| University Hospitals Geneva Medical Center | |
| 870 West Main Street, Geneva, Ohio 44041 | |
| (440) 466-1141 | |
| Name | University Hospitals Geneva Medical Center |
|---|---|
| Type | Critical Access Hospital |
| Location | 870 West Main Street, Geneva, Ohio |
| Ownership | Voluntary non-profit - Private |
| Emergency Services | Yes |
| Medicare ID (CCN) | 361307 |
| NPI Number | 1225128432 |
| Organization Name | UNIVERSITY HOSPITALS GENEVA MEDICAL CENTER |
| Doing Business As | THE MEMORIAL HOSPITAL OF GENEVA |
| Address | 870 W Main St, Geneva, OH 44041 |
| Hospital Type | General Acute Care Hospital - Critical Access |
| Phone Number | 216-767-8793 |
News Archive
Smiths Medical, a leading global medical device manufacturer, today announced it is to establish a wholly-owned subsidiary in Mumbai, India, to help grow its business in this vitally important part of the world.
Protalix BioTherapeutics, Inc., announced today it has submitted validation data regarding the Company's manufacturing process for taliglucerase alfa to the U.S. Food and Drug Administration (FDA). The Company made the submission in response to a request from the FDA for validation data from the Company's upgraded manufacturing facility. The FDA is currently reviewing the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease.
Health authorities worldwide are coping with rising costs and disability resulting from fragility fractures in the older population.
Allied Healthcare Group (ASX: AHZ) has announced an update on the progress of Coridon, its investment company founded by Professor Ian Frazer and working on developing the next generation of vaccines. Included in these activities, Cordon has entered into a license agreement with Nature Technology Corporation (NTC) and has contracted VGXI Inc. in the US for production of clinical material for the Phase I study scheduled to begin later this year.
Aeterna Zentaris Inc. today announced that it has reached an agreement with the U.S. Food and Drug Administration ("FDA") on a Special Protocol Assessment ("SPA") for an upcoming Phase 3 registration trial in endometrial cancer with its doxorubicin peptide conjugate, AEZS-108. The SPA agreement states that the proposed trial protocol design, clinical endpoints and planned analyses are acceptable to the FDA to support a regulatory submission.
› Verified 6 days ago
| NPI Number | 1326125956 |
| Organization Name | UHHS - HEATHER HILL REHABILITATION HOSPITAL INC |
| Doing Business As | UNIVERSITY HOSPITALS EXTENDED CARE CAMPUS - LTCH |
| Address | 12340 Bass Lake Rd, Chardon, OH 44024 |
| Hospital Type | Long Term Care Hospital |
| Phone Number | 216-767-8793 |
News Archive
Smiths Medical, a leading global medical device manufacturer, today announced it is to establish a wholly-owned subsidiary in Mumbai, India, to help grow its business in this vitally important part of the world.
Protalix BioTherapeutics, Inc., announced today it has submitted validation data regarding the Company's manufacturing process for taliglucerase alfa to the U.S. Food and Drug Administration (FDA). The Company made the submission in response to a request from the FDA for validation data from the Company's upgraded manufacturing facility. The FDA is currently reviewing the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease.
Health authorities worldwide are coping with rising costs and disability resulting from fragility fractures in the older population.
Allied Healthcare Group (ASX: AHZ) has announced an update on the progress of Coridon, its investment company founded by Professor Ian Frazer and working on developing the next generation of vaccines. Included in these activities, Cordon has entered into a license agreement with Nature Technology Corporation (NTC) and has contracted VGXI Inc. in the US for production of clinical material for the Phase I study scheduled to begin later this year.
Aeterna Zentaris Inc. today announced that it has reached an agreement with the U.S. Food and Drug Administration ("FDA") on a Special Protocol Assessment ("SPA") for an upcoming Phase 3 registration trial in endometrial cancer with its doxorubicin peptide conjugate, AEZS-108. The SPA agreement states that the proposed trial protocol design, clinical endpoints and planned analyses are acceptable to the FDA to support a regulatory submission.
› Verified 6 days ago
| NPI Number | 1720386253 |
| Organization Name | MUNSON HEALTHCARE, INC. |
| Doing Business As | HEATHER HILL CARE COMMUNITIES |
| Address | 12340 Bass Lake Rd, Chardon, OH 44024 |
| Hospital Type | Long Term Care Hospital |
| Phone Number | 440-285-4040 |
News Archive
Smiths Medical, a leading global medical device manufacturer, today announced it is to establish a wholly-owned subsidiary in Mumbai, India, to help grow its business in this vitally important part of the world.
Protalix BioTherapeutics, Inc., announced today it has submitted validation data regarding the Company's manufacturing process for taliglucerase alfa to the U.S. Food and Drug Administration (FDA). The Company made the submission in response to a request from the FDA for validation data from the Company's upgraded manufacturing facility. The FDA is currently reviewing the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease.
Health authorities worldwide are coping with rising costs and disability resulting from fragility fractures in the older population.
Allied Healthcare Group (ASX: AHZ) has announced an update on the progress of Coridon, its investment company founded by Professor Ian Frazer and working on developing the next generation of vaccines. Included in these activities, Cordon has entered into a license agreement with Nature Technology Corporation (NTC) and has contracted VGXI Inc. in the US for production of clinical material for the Phase I study scheduled to begin later this year.
Aeterna Zentaris Inc. today announced that it has reached an agreement with the U.S. Food and Drug Administration ("FDA") on a Special Protocol Assessment ("SPA") for an upcoming Phase 3 registration trial in endometrial cancer with its doxorubicin peptide conjugate, AEZS-108. The SPA agreement states that the proposed trial protocol design, clinical endpoints and planned analyses are acceptable to the FDA to support a regulatory submission.
› Verified 6 days ago
| NPI Number | 1902996119 |
| Organization Name | UNIVERSITY HOSPITALS CONNEAUT MEDICAL CENTER |
| Doing Business As | THE BROWN MEMORIAL HOSPITAL |
| Address | 158 W Main Rd, Conneaut, OH 44030 |
| Hospital Type | General Acute Care Hospital - Critical Access |
| Phone Number | 216-767-8793 |
News Archive
Smiths Medical, a leading global medical device manufacturer, today announced it is to establish a wholly-owned subsidiary in Mumbai, India, to help grow its business in this vitally important part of the world.
Protalix BioTherapeutics, Inc., announced today it has submitted validation data regarding the Company's manufacturing process for taliglucerase alfa to the U.S. Food and Drug Administration (FDA). The Company made the submission in response to a request from the FDA for validation data from the Company's upgraded manufacturing facility. The FDA is currently reviewing the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease.
Health authorities worldwide are coping with rising costs and disability resulting from fragility fractures in the older population.
Allied Healthcare Group (ASX: AHZ) has announced an update on the progress of Coridon, its investment company founded by Professor Ian Frazer and working on developing the next generation of vaccines. Included in these activities, Cordon has entered into a license agreement with Nature Technology Corporation (NTC) and has contracted VGXI Inc. in the US for production of clinical material for the Phase I study scheduled to begin later this year.
Aeterna Zentaris Inc. today announced that it has reached an agreement with the U.S. Food and Drug Administration ("FDA") on a Special Protocol Assessment ("SPA") for an upcoming Phase 3 registration trial in endometrial cancer with its doxorubicin peptide conjugate, AEZS-108. The SPA agreement states that the proposed trial protocol design, clinical endpoints and planned analyses are acceptable to the FDA to support a regulatory submission.
› Verified 6 days ago
| Able to receive lab results electronically | Yes |
| Able to track patients' lab results, tests, and referrals electronically between visits | Yes |
News Archive
Smiths Medical, a leading global medical device manufacturer, today announced it is to establish a wholly-owned subsidiary in Mumbai, India, to help grow its business in this vitally important part of the world.
Protalix BioTherapeutics, Inc., announced today it has submitted validation data regarding the Company's manufacturing process for taliglucerase alfa to the U.S. Food and Drug Administration (FDA). The Company made the submission in response to a request from the FDA for validation data from the Company's upgraded manufacturing facility. The FDA is currently reviewing the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease.
Health authorities worldwide are coping with rising costs and disability resulting from fragility fractures in the older population.
Allied Healthcare Group (ASX: AHZ) has announced an update on the progress of Coridon, its investment company founded by Professor Ian Frazer and working on developing the next generation of vaccines. Included in these activities, Cordon has entered into a license agreement with Nature Technology Corporation (NTC) and has contracted VGXI Inc. in the US for production of clinical material for the Phase I study scheduled to begin later this year.
Aeterna Zentaris Inc. today announced that it has reached an agreement with the U.S. Food and Drug Administration ("FDA") on a Special Protocol Assessment ("SPA") for an upcoming Phase 3 registration trial in endometrial cancer with its doxorubicin peptide conjugate, AEZS-108. The SPA agreement states that the proposed trial protocol design, clinical endpoints and planned analyses are acceptable to the FDA to support a regulatory submission.
› Verified 6 days ago
University Hospitals Geneva Medical Center Critical Access Hospital Location: 870 West Main Street, Geneva, Ohio 44041 Phone: (440) 466-1141 | |
Generations Behavioral Health - Geneva Psychiatric Hospital Location: 60 West Street, Geneva, Ohio 44041 Phone: (440) 415-0794 |